MZL-IPI Risk-adapted Targeted Therapy in Untreated MZL

Clinical trial NCT06793189 · RECRUITING

Trial details

NCT number: NCT06793189
Sponsor: Ruijin Hospital
Status: RECRUITING
Phase: Phase 2
Study type: INTERVENTIONAL

Marginal Zone Lymphoma(MZL)

Start date: 2025-01-23
Primary completion: 2028-12-31
Enrollment: 145

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.